Coordinated Antimicrobial Drug/Device Development Addressed In FDA Final Guidance
Executive Summary
In its bid to fight antimicrobial resistance, the agency has finalized a 2016 guidance on how novel antibiotic developers can coordinate with antimicrobial susceptibility test-makers to ensure their products come to market at about the same time. The agency recommends using its pre-submission process for a more efficient review.